ELOX - Eloxx Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
10.57
-0.38 (-3.47%)
At close: 4:00PM EDT

10.57 0.00 (0.00%)
After hours: 4:39PM EDT

Stock chart is not supported by your current browser
Previous Close10.95
Open11.17
Bid10.28 x 1100
Ask16.50 x 800
Day's Range10.46 - 11.17
52 Week Range9.12 - 24.60
Volume30,036
Avg. Volume27,827
Market Cap380.788M
Beta (3Y Monthly)2.33
PE Ratio (TTM)N/A
EPS (TTM)-1.46
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.80
Trade prices are not sourced from all markets
  • ACCESSWIRE10 hours ago

    SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Eloxx Pharmaceuticals, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

    NEW YORK, NY / ACCESSWIRE / May 21, 2019 / Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty ...

  • Thomson Reuters StreetEvents2 days ago

    Edited Transcript of ELOX earnings conference call or presentation 9-May-19 12:30pm GMT

    Q1 2019 Eloxx Pharmaceuticals Inc Earnings Call

  • Eloxx Pharmaceuticals, Inc. (ELOX) Q1 2019 Earnings Call Transcript
    Motley Fool12 days ago

    Eloxx Pharmaceuticals, Inc. (ELOX) Q1 2019 Earnings Call Transcript

    ELOX earnings call for the period ending March 31, 2019.

  • GlobeNewswire13 days ago

    Eloxx Pharmaceuticals Reports First Quarter 2019 Financial and Operating Results and Provides Business Update

    Positive new preclinical data for Eloxx ERSG molecules presented at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting May 2, 2019 demonstrated:.

  • GlobeNewswire20 days ago

    Eloxx Pharmaceuticals Presents Positive New Data at the Association for Research in Vision and Ophthalmology “ARVO” 2019 Annual Meeting

    Eloxx Pharmaceuticals, Inc. (“Eloxx”), (ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis, inherited retinal disorders, and other diseases caused by nonsense mutations limiting production of functional proteins, today presented new findings related to preclinical inherited retinal disease therapeutic development at the ARVO 2019 Annual Meeting in Vancouver, BC on May 2, 2019. “We are very pleased with the preclinical results for several of our ERSG compounds   demonstrating that they are suitable for intravitreal injection, well-tolerated in a sensitive model species, active against Usher Syndrome mutations and capable of reaching the retina.

  • GlobeNewswirelast month

    Eloxx Pharmaceuticals to Report First Quarter 2019 Financial Results and Provide Business Update on May 9, 2019

    Eloxx Pharmaceuticals, Inc. (ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis, inherited retinal diseases and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that it will release its first quarter 2019 financial and operational results and host a conference call and live webcast on Thursday, May 9, 2019. Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are formulated to treat rare and ultra-rare premature stop codon diseases.

  • GlobeNewswirelast month

    Eloxx Pharmaceuticals to Participate in the 2019 5th Annual SunTrust Robinson Humphrey (STRH) Life Sciences Summit on May 7, 2019

    Eloxx Pharmaceuticals, Inc. (ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis, inherited retinal disorders and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that Robert E. Ward, Chairman and Chief Executive Officer of Eloxx, will host one-on-one meetings with investors at the 5th Annual STRH Life Sciences Summit on May 7, 2019, at the Lotte New York Palace in New York, NY. Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are formulated to treat rare and ultra-rare premature stop codon diseases.

  • ACCESSWIRElast month

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by the Board of Directors of Eloxx Pharmaceuticals, Inc.

    NEW YORK, NY / ACCESSWIRE / April 11, 2019 / Levi & Korsinsky announces it has commenced an investigation of Eloxx Pharmaceuticals, Inc. (NASDAQGM: ELOX) concerning possible breaches of fiduciary duty. ...

  • GlobeNewswire2 months ago

    Eloxx Pharmaceuticals Presents Positive New Data for Lead Investigational Drug, ELX-02, at the European Cystic Fibrosis Society (ECFS) Basic Science Conference

    ELX-02 shows significant increases in CFTR protein expression and localization correlating with functional activity in Cystic Fibrosis patient-derived organoids bearing CFTR.

  • Proteostasis Plunges on Weak Data From Cystic Fibrosis Study
    Zacks2 months ago

    Proteostasis Plunges on Weak Data From Cystic Fibrosis Study

    Proteostasis (PTI) announces data from a phase I study evaluating its triplet combination in cystic fibrosis. Although data were promising, it was weaker than rival Vertex's triplet combinations.

  • GlobeNewswire2 months ago

    Eloxx Pharmaceuticals to Present at the Guggenheim Rare Disease & Genomic Medicines Day on April 2, 2019

    Eloxx Pharmaceuticals, Inc. (ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis, inherited retinal disorders, and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that Robert E. Ward, Chairman and Chief Executive Officer of Eloxx, will host one-on-one meetings with investors at the Guggenheim Rare Disease & Genomic Medicines Day on April 2, 2019, at Le Meridien Cambridge in Boston, Ma. Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are formulated to treat rare and ultra-rare premature stop codon diseases.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of ELOX earnings conference call or presentation 8-Mar-19 1:00pm GMT

    Q4 2018 Eloxx Pharmaceuticals Inc Earnings Call

  • Eloxx Pharmaceuticals, Inc. (ELOX) Q4 2018 Earnings Conference Call Transcript
    Motley Fool2 months ago

    Eloxx Pharmaceuticals, Inc. (ELOX) Q4 2018 Earnings Conference Call Transcript

    ELOX earnings call for the period ending December 31, 2018.

  • GlobeNewswire2 months ago

    Eloxx Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial and Operating Results and Provides Business Update

    Eloxx announces the hiring of Dr. Susan Schneider as SVP Ophthalmology to lead the development of its rare inherited retinal disease programs Abstract accepted for presentation.

  • GlobeNewswire3 months ago

    Eloxx Pharmaceuticals to Present at the Oppenheimer 29th Annual Healthcare Conference on March 20, 2019

    Eloxx Pharmaceuticals, Inc. (ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis, inherited retinal disorders, and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that Robert E. Ward, Chairman and Chief Executive Officer of Eloxx, will make a company presentation and host one-on-one meetings with investors at the Oppenheimer 29th Annual Healthcare Conference on Wednesday, March 20, 2019, at the Westin New York Grand Central. Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are formulated to treat rare and ultra-rare premature stop codon diseases.

  • GlobeNewswire3 months ago

    Eloxx Pharmaceuticals Announces Participation in the HIT-CF Project on Cystic Fibrosis

    Eloxx Pharmaceuticals, Inc., (ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, inherited retinal diseases and other diseases caused by nonsense mutations limiting production of functional proteins, today announced it joined the consortium agreement of the European HIT-CF project, a European Union funded preclinical and clinical research program evaluating the efficacy and safety of several disease modifying drug candidates in Cystic Fibrosis (CF) patients with rare genetic mutations. Eloxx’s lead investigational drug candidate, ELX-02, a small molecule eukaryotic ribosomal selective glycoside (ERSG), will be evaluated in cystic fibrosis patients with nonsense mutations for whom there are few available treatment options.

  • GlobeNewswire3 months ago

    Eloxx Pharmaceuticals to Present at the Barclays Global Healthcare Conference on March 14, 2019

    Eloxx Pharmaceuticals, Inc. (ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis, inherited retinal disorders, and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that Robert E. Ward, Chairman and Chief Executive Officer of Eloxx, will make a company presentation and host one-on-one meetings with investors at the Barclays Global Healthcare Conference on Thursday, March 14, 2019, at the Loews Miami Beach Hotel. Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are formulated to treat rare and ultra-rare premature stop codon diseases.

  • GlobeNewswire3 months ago

    Eloxx Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference on Monday, March 11, 2019

    Eloxx Pharmaceuticals, Inc. (ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis, inherited retinal disorders, and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that Robert E. Ward, Chairman and Chief Executive Officer of Eloxx, will make a company presentation and host one-on-one meetings with investors at the Cowen and Company 39th Annual Health Care Conference on Monday, March 11, 2019, at the Boston Marriott Copley Place. Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are formulated to treat rare and ultra-rare premature stop codon diseases.

  • GlobeNewswire3 months ago

    Eloxx Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference in New York City on Friday, March 1, 2019

    Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are formulated to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA.

  • GlobeNewswire3 months ago

    Eloxx Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results and Provide Business Update on March 8, 2019

    Eloxx Pharmaceuticals, Inc. (ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis, inherited retinal diseases and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that it will release its fourth quarter and full year 2018 financial and operational results and host a conference call and live webcast on Friday, March 8, 2019. Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are formulated to treat rare and ultra-rare premature stop codon diseases.

  • GlobeNewswire4 months ago

    Eloxx Pharmaceuticals to Present at the 2019 BIO CEO and Investor Conference in New York City on Monday, February 11, 2019

    Eloxx Pharmaceuticals, Inc., (ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis, inherited retinal disorders, and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that Robert E. Ward, Chairman and Chief Executive Officer of Eloxx, will make a company presentation and host one-on-one meetings with investors at the 2019 BIO CEO and Investor Conference on Monday, February 11, 2019, at the New York Marriott Marquis Hotel. Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are formulated to treat rare and ultra-rare premature stop codon diseases.

  • GlobeNewswire5 months ago

    Eloxx Pharmaceuticals to Participate in a Panel Discussion at the BIOTECH SHOWCASE™ in San Francisco on Wednesday, January 9, 2019

    Eloxx Pharmaceuticals, Inc., (ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis, inherited retinal disorders, and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that David P. Snow, Chief Business Officer of Eloxx, will participate in a panel discussion titled “Rare and Orphan Diseases: the biotech industry is making a dent in treatment and diagnosis” at the BIOTECH SHOWCASE™ on Wednesday, January 9, 2019, at the Hilton San Francisco, Union Square. On December 21, 2018, Eloxx was added to the NASDAQ Biotechnology Index (NASDAQ:NBI).

  • Could The Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) Ownership Structure Tell Us Something Useful?
    Simply Wall St.5 months ago

    Could The Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) Ownership Structure Tell Us Something Useful?

    A look at the shareholders of Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) can tell us which group is most powerful. Institutions often own shares in more established companies, while it's not unusual Read More...

  • Waltham's Eloxx aims to reach cystic fibrosis patients that Vertex can't
    American City Business Journals5 months ago

    Waltham's Eloxx aims to reach cystic fibrosis patients that Vertex can't

    The Waltham startup is taking on the market giant Vertex Pharmaceuticals by developing an injection that targets the 10 percent of patients that Vertex and others haven't touched.